Financials data is unavailable for this security.
View more
Year on year Hester Biosciences Ltd had net income fall -29.06% from 266.27m to 188.89m despite a 14.45% increase in revenues from 2.66bn to 3.05bn. An increase in the cost of goods sold as a percentage of sales from 35.91% to 40.13% was a component in the falling net income despite rising revenues.
| Gross margin | 71.13% |
|---|---|
| Net profit margin | 8.42% |
| Operating margin | 15.07% |
| Return on assets | 3.89% |
|---|---|
| Return on equity | 8.04% |
| Return on investment | 4.91% |
More ▼
Cash flow in INRView more
In 2024, Hester Biosciences Ltd did not generate a significant amount of cash. However, the company earned 481.34m from its operations for a Cash Flow Margin of 15.81%. In addition the company used 226.54m on investing activities and also paid 260.45m in financing cash flows.
| Cash flow per share | 49.73 |
|---|---|
| Price/Cash flow per share | 48.11 |
| Book value per share | 354.81 |
|---|---|
| Tangible book value per share | 350.11 |
More ▼
Balance sheet in INRView more
| Current ratio | 1.75 |
|---|---|
| Quick ratio | 1.22 |
| Total debt/total equity | 0.8085 |
|---|---|
| Total debt/total capital | 0.4371 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -25.00% and -29.06%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
| Div yield(5 year avg) | 0.48% |
|---|---|
| Div growth rate (5 year) | -11.42% |
| Payout ratio (TTM) | 21.75% |
| EPS growth(5 years) | -14.59 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -11.62 |
More ▼
